Background: This study was designed to examine the responses to and the mechanism by which purinergic agonists decrease vascular resistance in the mesenteric vascular bed of the cat.
Methods and Results: Injections of ATP, UTP, and 2-MethylThioATP (2-MetSATP) into the mesenteric perfusion circuit elicited dose-dependent decreases in perfusion pressure while injections of P,y-MethylATP (f3,y-MetATP) produced a biphasic response with an initial vasopressor response followed by a vasodilator response. The order of potency of the vasodilator response was 2-MetSATP > ATP > UTP > P,y-MetATP. The vasodilator responses to ATP, UTP, 2-MetSATP, and P,y-MetATP were increased in duration by the cAMP phosphodiesterase inhibitor, rolipram. However, vasodilator responses were not altered by the adminstration of a nitric oxide synthase inhibitor, a cGMP phosphodiesterase inhibitor, or a cyclooxygenase inhibitor. Treatment with PPADS, a P2X,, P2Y, and P2Y4 receptor antagonist, did not alter vasodilator responses to the purinergic agonists; however, the vasopressor component of the response to P,y-MetATP was decreased.
Conclusions: These data suggest that ATP, UTP, 2-MetSATP, and P,Y-MetATP dilate the mesentary vascular bed in the cat by a cAMP dependent mechanism, and that nitric oxide or prostaglandin release, cGMP accumulation, or activation of P2X,, P2Y, or P2Y4 receptors play little or no role in mediating vasodilator responses to the purinergic agonists in this regional vascular bed. In addition, these results suggest that the pressor component of the response to P,y-MetATP is mediated by the activation of P2X, receptors.
1. Drury A, Szent-Gyorgyi A. The physiological activity of adenine compounds with especial reference to their actions upon mammalian heart. J Physiol (Lond)68:213-213, 1929
2.
2. Ralevic V, Bumstock G. Receptors for purines and pyrimidines. Pharmac Rev50:413-413, 1998
3.
3. Burnstock G. A basis for distinguishing two types of purinergic receptor. In Straub R, Bolis L (eds): Cell Membrane Receptors for Drugs and Hormones: A Multidisciplinary Approach. Raven Press, New York, pp. 107-118, 1978
4.
4. Abbracchio M, Bumstock G. Purinoceptors: Are there families of P2X and P2Y purinoceptors?Pharm Ther64: 445-445, 1994
5.
5. Shirasawa Y, White R, Robertson J. Mechanisms of the contractile effect induced by uridine 5-triphosphate in canine cerebral arteries. Stroke14:347-347, 1983
6.
6. Brown I, Thompson C, Belloni F. Mechanisms of coronary vasodilatation produced by ATP in guinea-pig isolated perfused heart. Br J Pharm105:211-211, 1992
7.
7. Taylor E, Parsons M, Wright P, Pipkin M, Howson W. The effects of adenosine triphosphate and related purines on arterial resistance vessels in vitro and in vivo. Eur J Pharm161:121-121, 1989
8.
8. Tada S, Okajima F, Mitsui Y, Kondo Y, Ui M. P2 purinoceptor-mediated cyclic AMP accumulation in bovine vascular smooth muscle cells. Eur J Pharm227:25-25, 1992
9.
9. Bean B. Pharmacology and electrophysiology of ATP-activated ion channels. Trends in Pharm Sci13:87-87, 1992
10.
10. Dubyak G, el-Moatassim C. Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol265:C577-C577, 1993
11.
11. Collo G, North R, Kawashima E, et al. Cloning of P2X5 and P2X6 receptors and the distribution and properties of an extended family of ATP-gated ion channels. J Neurosci16:2495-2495, 1996
12.
12. Lambrecht G, Freibe T, Grimm U, et al. PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur J Pharm217:217-217, 1992
13.
13. Champion H, Kadowitz P. R-(-)alpha-methyl-histamine has nitric oxide-mediated vasodilator activity in the mesenteric vascular bed of the cat. Eur J Pharm343:209-209, 1998
14.
14. Chinellato A, Froldi G, Caparrotta L, Ragazzi E. Pharmacolgical characterization of endothelial cell nitric oxide synthase inhibitors in isolated rabbit aorta. Life Sci62:479-479, 1998
15.
15. McCullough W, Collins D, Ellsworth M. Arteriolar responses to extracellular ATP in striated muscle. Am J Physiol272:H1886-H1886, 1997
16.
16. Ralevic V, Burnstock G. Effects of purines and pyrimidines on the rat mesenteric arterial bed. Circ Res69:1583-1583, 1991
17.
17. Lustig K, Erb L, Landis D, et al. Mechanisms by which extracellular ATP and UTP stimulate the release of prostacyclin from bovine pulmonary artery endothelial cells. Biochem Biophys Acta1134:61-61, 1987
18.
18. Needham L, Cusack N, Pearson J, Gordon L. Characteristics of the P2 purinoceptor that mediates prostacyclin production by pig aortic endothelial cells. Eur J Pharm134:199-199, 1987
19.
19. Yakushi Y, Watanabe A, Murayama T, Nomura Y. P2 purinoceptor mediated stimulation of adenyl cyclase in PC12 cells. Eur J Pharm314:243-243, 1996
20.
20. Vuorinen P, Porsti I, Metsa-Ketela T, Manninen V, Vapaatalo H, Laustiola K. Endothelium-dependent and independent effects of exogenous ATP, adenosine, GTP, and guanosine, on vascular tone and cyclic nucleotide accumulation of rat mesenteric artery. Br J Pharm105: 279-279, 1992
21.
21. Pelligrino D, Wang Q. Cyclic nucleotides cross talk and the regulation of cerebral vasodilation. Prog Neurobiol56: 1-1, 1998
22.
22. Brown C, Tanna B, Boarder M. PPADS: An antagonist at endothelial P2y-purinoceptors but not to P2u-purinoceptors. Br J Pharm116:2143-2143, 1995
23.
23. Tada S, Okajima F, Mitsui Y, Kondo Y, Ui M. P2 purinoceptor-mediated cyclic AMP accumulation in bovine vascular smooth muscle cells. Eur J Pharm227:25-25, 1992
24.
24. Post S, Jacobson J, Insel P. P2 purinergic receptor agonists enhance cAMP production in Madin-Darby canine kidney epithelial cells via an autocrine/paracrine mechanism. J Biol Chem271:2029-2029, 1996
